How to Avoid a Fall by Balancing Cost and Performance in Drug Discovery
Balancing cost and performance in drug discovery requires a hybrid engineering‑led approach that combines on‑premise HPC with scalable cloud resources. Uncontrolled cloud scaling can drive unpredictable expenses, while pure on‑premise systems demand high upfront capital and maintenance. By implementing disciplined job scheduling, auto‑scaling down, and robust monitoring, organizations can maintain reproducibility and accelerate research without waste. The article emphasizes training scientists in compute economics to bridge the skills gap.
Altesa BioSciences Raises $75M Series B
Altesa BioSciences announced an oversubscribed $75 million Series B round, led by Forbion with participation from Sanofi and existing backers Medicxi, Pitango, and Atlantic Partners. The financing will support the development of its lead candidate, vapendavir, targeting viral-driven exacerbations in COPD and...
5-Day Preoperative Radiotherapy in High-Risk STS Shows Manageable Toxicity
A phase‑2 single‑center trial evaluated a five‑day pre‑operative radiotherapy schedule in 110 patients with high‑risk soft‑tissue sarcoma. At two‑year follow‑up, grade ≥ 2 radiation‑related toxicities were observed in 14 of 74 evaluable patients, with lower rates in the extension cohort. Major wound...
At an Inflection Point in HIV Science: Nicolas Chomont, PhD, Looks Ahead to CROI 2026
Nicolas Chomont, chair of CROI 2026’s scientific program, previewed the conference’s focus on emerging HIV research, including treatment, cure, and vaccine advances. The meeting will showcase extensive data on long‑acting antiretroviral therapies and address funding constraints affecting global HIV initiatives....
Ten63 Therapeutics Secures New Funding
Ten63 Therapeutics, an AI‑driven drug‑discovery firm spun out of Duke and TTIC, announced a strategic investment from Chugai Venture Fund and the Bill & Melinda Gates Foundation, bringing total capital to over $45 million. The company leverages its BEYOND generative‑chemistry platform...
Hormone-Regulated Immune Cells Implicated in Longer Lasting Pain in Women
Researchers at Michigan State University discovered that hormone‑regulated monocytes producing interleukin‑10 (IL‑10) drive faster pain resolution in males. In mouse models, testosterone‑dependent IL‑10+ monocytes cleared inflammatory pain more quickly, while females exhibited fewer of these cells and prolonged pain. Human...
New Insights Into How Bacteria Control DNA Synthesis Open the Door to Next Generation Antimicrobials
Researchers have solved the crystal structure of the bacterial transcriptional regulator NrdR and shown how its assembly shifts in response to ATP and dATP, directly controlling ribonucleotide reductase (RNR) gene expression. The work, performed on Escherichia coli and Pseudomonas aeruginosa,...
Kansas City Launches Integrated Theranostics Platform Partnership
A public‑private partnership between the University of Kansas Health System, KU Medical Center, Children’s Mercy and Bold Advanced Medical Future (BAMF) Health is launching an integrated theranostics platform in Kansas City. The center will combine molecular imaging, radiopharmaceutical production, clinical...
In the Clinic for Feb. 20, 2026
The February 20 2026 "In the Clinic" roundup aggregates a broad set of industry snapshots, special reports, and infographics covering biopharma, medical technology, and emerging research areas. It links to data on mRNA vaccine research, China’s GLP‑1 market, pulsed‑field ablation for atrial...
Generic Drugs Forum (GDF) 2026 - 04/22/2026
On April 22‑23, 2026, the FDA’s Center for Drug Evaluation and Research hosted the annual Generic Drugs Forum at its White Oak Campus, with a virtual option via Adobe Connect. The two‑day event gathered generic drug developers, consultants, and regulatory...
Macrophage Phenotype–Dependent Protein Corona Formation Governs Ligand Accessibility and Immune Clearance of Biomimetic Nanoparticles
Researchers coated magnetic silica nanoparticles with membranes from naïve (M0), classically activated (M1) and alternatively activated (M2) macrophages to study phenotype‑dependent protein corona formation. Proteomic analysis showed M0‑derived membranes adsorbed the fewest opsonins (C3, IgG, IgM) and triggered the lowest...
A Quercetin Nanocarrier‐Loaded Dual Network Injectable Hydrogel for Mesenchymal Stem Cells (MSCs) Delivery Targeting Osteoarthritis
Researchers have created an injectable dual‑network hydrogel composed of gelatin methacrylate and κ‑carrageenan that embeds quercetin‑loaded PLGA nanoparticles for mesenchymal stem cell (MSC) delivery in osteoarthritis (OA). The antioxidant hydrogel scavenges reactive oxygen species, reprograms M1 macrophages to an anti‑inflammatory...
STAT+: Pharmalittle: We’re Reading About an FDA Official’s Speech, a Grail Cancer Blood Test, and Much More
FDA drug‑center head Tracy Beth Høeg used her first staff address to flag two priority areas: the safety of antidepressants taken during pregnancy and the use of monoclonal antibodies that protect infants from RSV. She also signaled a continued interest...
FDA Starts Review of Regeneron's Drug for Rare Disease FOP
The FDA has placed Regeneron's anti‑activin A antibody garetosmab under priority review, with a decision expected by August. Phase 3 OPTIMA data showed a 94% reduction in new heterotopic ossification lesions at the lower dose and a 90% reduction at the higher...
Inside Oxford’s Biotech Hub: A Scientific Powerhouse Situated in the U.K.’s Golden Triangle
Oxford has cemented its status as a leading European biotech hub, anchored by the University of Oxford’s deep biomedical expertise and a thriving spin‑out ecosystem. The Oxford Science Park now houses nearly 100 life‑science companies, while the £1.2 bn Oxford North...
Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma
Frontline treatment of diffuse large B‑cell lymphoma (DLBCL) is shifting from traditional R‑CHOP toward targeted and bispecific antibody‑based regimens. The POLARIX phase‑3 trial demonstrated that Pola‑R‑CHP improves progression‑free survival, particularly in activated‑B‑cell (ABC) disease and older patients. Early phase studies...
Nanozyme Aptasensor: A Breakthrough in S. Aureus Diagnostics
Researchers have unveiled a nanozyme‑aptamer colorimetric array that classifies Staphylococcus aureus strains with 100% accuracy, including methicillin‑resistant variants. The platform couples gold‑nanoparticle nanozymes with four strain‑specific aptamers, producing distinct color fingerprints that are decoded by hierarchical clustering and linear discriminant...
No One-Trick Pony in Oncology, Merck’s Cancer Footprint Is Expanding
Merck is expanding beyond its flagship Keytruda by investing in diverse oncology platforms. In 2024 it spent $700 million on a bispecific candidate from Curon and $680 million to acquire Harpoon Therapeutics, bolstering its T‑cell engager portfolio. The company is also advancing...
FDA Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
The FDA approved a fixed‑dose combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma. The decision is based on the AMPLIFY trial, which showed a 35% reduction in progression‑free survival risk compared...
The US FDA Accepts Roche’s Giredestrant NDA for ESR1-Mutated, ER-Positive Advanced Breast Cancer
The U.S. FDA has accepted Roche’s new drug application for giredestrant combined with everolimus to treat ER‑positive, HER2‑negative, ESR1‑mutated advanced breast cancer. Phase III evERA data show a 44% reduction in disease progression or death overall and a 62% reduction in...
UK Firm Steps in to Ease Medicine Supply Crisis in NHS
A shortage of bone cement from German supplier Heraeus Medical threatens NHS orthopaedic surgeries, potentially lasting two months. NHS England has asked trusts to prioritise emergency joint replacements, leaving elective patients at risk. UK‑based Biocomposites accelerated the launch of its...
Novartis to Divest India Unit to Private Equity-Led Consortium for $159M
Novartis announced the sale of its majority stake in its Indian generics and prescription business to a private‑equity‑led consortium for $159 million. The transaction transfers control of a portfolio that includes both off‑patent generics and branded medicines to the buyers. The...
Revealing Remarkable Genomic Architecture in Embryonic Reproductive Cells Prior to Sperm and Egg Development
Researchers led by Dr. Tien‑Chi Huang discovered a dramatic three‑dimensional reorganization of genome architecture in mouse and human embryonic germ cells as they enter meiosis. Centromeres relocate from the nuclear interior to the periphery, accompanied by reduced compartmentalization and increased...
Ex-Novartis CMO John Tsai Joins Daiichi Sankyo
Daiichi Sankyo appointed former Novartis chief medical officer John Tsai as its new CMO, succeeding Ken Takeshita after a five‑year tenure. Tsai brings a record of launching 160 projects and 15 regulatory approvals, including Zolgensma and Pluvicto, and recent experience leading biotech...
NexEos Bio Receives US FDA IND Clearance to Advance NTX-1024 Into P-II/III Study for Vernal Keratoconjunctivitis
U.S. FDA has granted IND clearance for NexEos Bio’s ophthalmic solution NTX-1024, allowing the company to commence a combined Phase II/III clinical trial in vernal keratoconjunctivitis (VKC). The upcoming study will assess safety and efficacy after an open‑label investigator‑initiated trial...
En Carta Diagnostics Receives FDA Breakthrough Device Designation for EC Pocket Lyme Test
En Carta Diagnostics announced that its EC Pocket Lyme test has received FDA Breakthrough Device Designation, accelerating its path to U.S. market entry. The point‑of‑need molecular assay detects Borrelia DNA directly from skin interstitial fluid using a microneedle sampler, delivering...
Serina Therapeutics Enrols First Patient for SER-252 Trial
Serina Therapeutics has enrolled the first patient in its Phase Ib registrational trial of SER‑252 for advanced Parkinson’s disease. The study, conducted with Parkinson’s Australia and Neuroscience Trials Australia, will assess safety, pharmacokinetics, tolerability and early efficacy, with dosing slated to...
Syngene and VivaMed Collaborate on Therapeutic Programmes
Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI‑derived drug repurposing programmes. The partnership combines Syngene’s pre‑clinical development capabilities with VivaMed’s AI‑generated therapeutic hypotheses, creating a pathway from computational hits to translational validation. Together they will...
Researchers Uncover Signalling Pathway Behind Nitrate-Stimulated Root Growth
Researchers identified a MAPKKK called MEKK14 that activates a nitrate‑driven signalling cascade in Arabidopsis thaliana. The cascade triggers the circadian transcription factor CCA1, which in turn up‑regulates MEKK14, forming a positive feedback loop. This loop amplifies auxin signaling, leading to...
Accelerating Rare Disease Cures with ASOs, Gene Editing, and AI
Professor Matthew Wood, Oxford’s leading neuroscientist, heads the Oxford‑Harrington Rare Disease Centre, a partnership designed to fast‑track therapies for rare neuromuscular and genetic disorders. He outlines a vision to make antisense oligonucleotides (ASOs) and gene‑editing tools more modular, scalable, and...
Boehringer Ingelheim Secures US FDA’s EUA for NexGard and NexGard COMBO to Treat NWS
Boehringer Ingelheim received an Emergency Use Authorization (EUA) from the U.S. FDA for its NexGard chewable tablets to treat New World screwworm (NWS) infestations in dogs and puppies, and for NexGard COMBO topical solution to treat NWS in cats and...
Grail's Cancer Test Misses Primary Study Goal in UK Study
Grail announced that its Galleri multi‑cancer blood test failed to achieve the primary endpoint in a large United Kingdom clinical trial. The study, which evaluated the test’s ability to detect early‑stage cancers across dozens of tumor types, showed promising signals...
This Biotech ETF Is a Catalyst-Rich Story
Biotech stocks and ETFs rebounded strongly last year, and the ALPS Medical Breakthroughs ETF (SBIO) is positioned to benefit from that momentum. SBIO tracks nearly 90 companies with drugs in Phase II or III trials, but it carries a modest YTD...
Electronic Mesh Spurs Islet Cell Maturation, Could Aid Diabetes Care
Researchers at the University of Pennsylvania and Harvard have created an ultrathin, flexible electronic mesh that can be implanted into developing pancreatic tissue. The mesh delivers a 24‑hour rhythmic electrical pulse, coaxing stem‑cell‑derived islet cells toward functional maturity and synchronized...
Vaccine Protects Against Multiple Respiratory Viruses, Bacteria, and Allergens in Mice
Stanford researchers have created an intranasal vaccine that elicits a combined innate‑adaptive response, providing broad lung protection in mice. The formulation, containing TLR agonists and a harmless antigen, shielded animals for at least three months against SARS‑CoV‑2, other coronaviruses, two...
Gel Helps Mini Spinal Cords to Heal From Injury
Researchers have engineered miniature, three‑dimensional spinal‑cord organoids that can be deliberately injured and subsequently repaired with a biocompatible gel. The gel promotes cell survival and rapid axonal regrowth, effectively modeling the healing cascade observed in vivo. This human‑derived platform provides...
Are Obesity Drugs Causing a Severe Complication? What the Science Says
The United Kingdom and Brazil have issued safety warnings linking GLP‑1 weight‑loss drugs to acute pancreatitis after recording 19 and 6 deaths respectively. Reports include roughly 1,300 UK and 145 Brazilian pancreatitis cases among millions of users, though the overall...
'Digital Blood Testing' Now at Hand
A collaborative team led by UNSW and Nutromics has demonstrated a wearable patch that continuously measures vancomycin levels using DNA‑based aptamer sensors. Published in Nature Biotechnology, the pilot trial showed the patch can track drug concentration in interstitial fluid, offering...
STAT+: Key Study of Grail’s Cancer Detection Test Fails in Setback for Company
Grail’s multi‑cancer blood test Galleri failed to meet its primary endpoint in a large NHS‑partnered study, casting doubt on its early‑detection claims. The test, priced at $1,000, generated $136.8 million from 185,000 units sold in 2025 but remains unapproved by the...
STAT+: In First Speech to Her FDA Staff, Høeg Says She’ll Scrutinize RSV Shots and SSRIs in Pregnancy
FDA Commissioner Tracy Beth Høeg, in her inaugural staff address, announced a renewed focus on evaluating the safety of antidepressants prescribed during pregnancy and monoclonal antibody RSV prophylaxis for infants. She highlighted gaps in existing safety monitoring and pledged more...
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
Novo Nordisk’s shares have slumped 66% from their 2024 peak, reflecting weak 2026 guidance and fierce competition from Eli Lilly in the GLP‑1 arena. The Danish firm recently introduced the first oral GLP‑1 pill, positioning it ahead of Lilly’s upcoming tablet and...
Lower Glucose by Living High
Researchers at Gladstone Institutes discovered that red blood cells (RBCs) act as a primary glucose sink during hypoxia, explaining why people living at high altitude have lower blood sugar. PET/CT scans showed 70% of the extra glucose clearance in hypoxic...
Lonza Boosts Advanced Synthesis Capabilities for Bioconjugates
Lonza has expanded its advanced synthesis portfolio to provide end‑to‑end support for antibody‑drug conjugates (ADCs) and other bioconjugates. The company fully integrated the Synaffix‑derived ADC platform—including GlycoConnect® conjugation, HydraSpace® spacers and toxSYN® linker payloads—into its services. A new dual‑payload ADC...
Machine Learning Streamlines the Complexities of Making Better Proteins
Researchers at UC Berkeley and the Arc Institute unveiled MULTI‑evolve, a machine‑learning framework that predicts how multiple amino‑acid mutations affect protein function in a single experimental round. The workflow first estimates single‑mutation effects, then measures pairwise interactions, and finally trains...
Stronger Scents and Healthier Crops: Unlocking Plants' Hidden Potential Through Precision Gene Editing
Researchers at Hebrew University used a virus‑based CRISPR/Cas9 system to edit the regulatory domain of the HMGR enzyme, removing its metabolic brake and dramatically increasing terpenoid production. The edit boosted scent intensity and flower size in petunias and enhanced flavor‑related...
A New Method to Decode How DNA 'Switches' Control Gene Activity
Researchers unveiled e2MPRA, a massively parallel reporter assay that simultaneously measures regulatory activity, chromatin accessibility, and H3K27ac modifications across thousands of cis‑regulatory elements. Validated on ~10,000 synthetic and native sequences, the method links single‑base mutations to multi‑layered gene‑regulatory outcomes. The...
Obesity Biotech Verdiva Plans Big Year of Data, Explores Deals
Verdiva Bio, an obesity‑focused biotech, is gearing up for a data‑heavy 2026, with Phase 2 results for its lead long‑acting peptide slated for the third quarter. The company is also courting strategic partnerships, eyeing potential deals with major pharma players after...
Redefining Obesity Treatment Beyond GLP-1 Limits
BioSpace’s Denatured podcast featured Verdiva Bio’s R&D head Jane Hughes and MitoRx CEO Jon Rees discussing next‑generation obesity therapies that move beyond the limitations of GLP‑1 agonists. They highlighted how GLP‑1 treatments can cause muscle loss and suffer from poor...
Biogen Stops Part of an MS Trial; Merck Reports More Enflonsia Data
Biogen announced it is halting the combination‑therapy arm of its multiple sclerosis (MS) trial after interim data showed insufficient efficacy and safety concerns. The decision pauses enrollment in the experimental regimen while the company continues evaluating its monotherapy components. Meanwhile,...
Valneva’s Lyme Disease Vaccine Offers Beacon of Hope Amid 2025 Sales Dip
Valneva reported a 3.3% decline in product sales to €157.9 million in 2025, driven primarily by regulatory suspensions of its chikungunya vaccine Ixchiq in the US and UK. Despite the sales dip, total revenue rose to €174.7 million, buoyed by a licensing...
